Profile data is unavailable for this security.
About the company
PureTech Health plc is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company's R&D engine has developed 27 therapeutics and therapeutic candidates, including two (Plenity and EndeavorRx) that have received both United States (US) Food and Drug Administration (FDA) clearance and European marketing authorization. The Company's pipeline includes LYT-100, LYT-200, LYT-300, LYT-310 and LYT-503/IMB-150. LYT-100 (deupirfenidone) is being advanced for the potential treatment of conditions involving inflammation and fibrosis. It is developing LYT-200 for the treatment of metastatic/locally advanced solid tumors that have poor survival rates, including urothelial and head and neck cancers. LYT-300 is an oral prodrug of allopregnanolone, which is being advanced for the potential treatment of anxiety disorders and postpartum depression.
- Revenue in USD (TTM)15.62m
- Net income in USD-50.35m
- Incorporated2015
- Employees111.00
- LocationPureTech Health PLC6 Tide Street, Suite 400BOSTON 02210United StatesUSA
- Phone+1 (617) 482-2333
- Fax+1 (617) 482-3337
- Websitehttps://puretechhealth.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lyell Immunopharma Inc | 84.20m | -181.93m | 721.37m | 274.00 | -- | 0.9203 | -- | 8.57 | -0.731 | -0.731 | 0.3356 | 3.14 | 0.0862 | -- | -- | 307,281.00 | -18.64 | -- | -19.35 | -- | -- | -- | -216.09 | -- | -- | -- | 0.00 | -- | 695.15 | -- | 26.82 | -- | -- | -- |
| Arcturus Therapeutics Holdings Inc | 281.04m | 111.27m | 721.72m | 170.00 | 7.24 | 2.19 | 6.38 | 2.57 | 3.75 | 3.75 | 10.30 | 12.40 | 0.6915 | -- | 5.84 | 1,653,177.00 | 27.38 | -25.20 | 36.16 | -31.59 | -- | -- | 39.59 | -118.84 | -- | -- | 0.00 | -- | 1,566.79 | 73.78 | 104.59 | -- | 98.45 | -- |
| 4D Molecular Therapeutics Inc | 2.21m | -109.84m | 726.44m | 137.00 | -- | 2.68 | -- | 329.15 | -3.38 | -3.38 | 0.068 | 6.58 | 0.0078 | -- | -- | 15,764.29 | -38.61 | -31.26 | -40.26 | -33.58 | -- | -- | -4,976.80 | -526.63 | -- | -- | 0.00 | -- | -82.65 | -11.58 | -50.73 | -- | 82.30 | -- |
| Bicycle Therapeutics PLC (ADR) | 15.50m | -124.22m | 727.65m | 236.00 | -- | 2.99 | -- | 46.95 | -4.17 | -4.17 | 0.5208 | 8.10 | 0.0349 | -- | 0.62 | 65,673.73 | -27.97 | -26.32 | -31.06 | -29.28 | -- | -- | -801.45 | -492.29 | -- | -- | 0.1112 | -- | 23.65 | 47.67 | -68.69 | -- | 76.36 | -- |
| Dyne Therapeutics Inc | 0.00 | -176.70m | 738.21m | 122.00 | -- | 3.05 | -- | -- | -3.33 | -3.33 | 0.00 | 4.15 | 0.00 | -- | -- | 0.00 | -52.25 | -- | -55.96 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -12.60 | -- | -- | -- |
| Anavex Life Sciences Corp | 0.00 | -52.74m | 753.41m | 38.00 | -- | 5.15 | -- | -- | -0.6768 | -0.6768 | 0.00 | 1.81 | 0.00 | -- | -- | 0.00 | -33.02 | -46.07 | -35.47 | -51.22 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -26.56 | -- | -- | -- |
| PureTech Health PLC (ADR) | 15.62m | -50.35m | 770.14m | 111.00 | -- | 1.39 | -- | 49.31 | -1.75 | -1.75 | 0.5427 | 19.46 | 0.019 | -- | 2.08 | 140,702.70 | -4.50 | 5.21 | -5.58 | 6.53 | -- | -- | -237.32 | 265.77 | -- | -2.46 | 0.0789 | 0.00 | -10.18 | 43.86 | 16.85 | -- | 0.046 | -- |
| Avidity Biosciences Inc | 9.66m | -192.15m | 771.93m | 186.00 | -- | 1.38 | -- | 79.89 | -3.36 | -3.36 | 0.1675 | 7.89 | 0.0187 | -- | -- | 51,946.24 | -37.13 | -- | -40.20 | -- | -- | -- | -1,988.76 | -- | -- | -- | 0.00 | -- | -1.09 | -- | -47.44 | -- | -- | -- |
| Ambrx Biopharma Inc - ADR | 5.81m | -70.65m | 773.76m | 66.00 | -- | 4.24 | -- | 133.11 | -1.77 | -1.77 | 0.1427 | 3.31 | -- | -- | -- | 88,075.76 | -- | -- | -- | -- | -- | -- | -1,215.40 | -- | -- | -- | 0.00 | -- | -0.7109 | -- | -14.57 | -- | -- | -- |
| Collegium Pharmaceutical Inc | 524.95m | -29.36m | 779.42m | 207.00 | -- | 4.33 | 6.31 | 1.48 | -0.8616 | -0.8616 | 15.39 | 5.20 | 0.4267 | 4.99 | 3.04 | 2,535,986.00 | -2.39 | 0.4411 | -3.51 | 0.7897 | 46.32 | 46.84 | -5.59 | 0.7013 | 1.13 | 1.14 | 0.8162 | 0.00 | 67.56 | 74.74 | -134.96 | -- | 256.95 | -- |
| Regenxbio Inc | 109.64m | -270.27m | 791.08m | 401.00 | -- | 1.70 | -- | 7.22 | -6.25 | -6.25 | 2.53 | 10.70 | 0.1237 | -- | 4.78 | 273,426.40 | -30.48 | -7.65 | -35.08 | -8.51 | 60.84 | 83.86 | -246.50 | -26.08 | -- | -20.10 | 0.00 | -- | -76.03 | 61.09 | -319.27 | -- | 33.82 | -- |
| Cogent Biosciences Inc | 0.00 | -148.19m | 796.73m | 138.00 | -- | 4.94 | -- | -- | -2.32 | -2.32 | 0.00 | 3.15 | 0.00 | -- | -- | 0.00 | -63.05 | -44.58 | -68.76 | -50.10 | -- | -- | -- | -881.92 | -- | -- | 0.00 | -- | -- | -- | -94.04 | -- | 49.73 | -- |
| Allogene Therapeutics Inc | 234.00k | -351.49m | 806.50m | 359.00 | -- | 1.36 | -- | 3,446.60 | -2.44 | -2.44 | 0.0016 | 4.06 | 0.0003 | -- | -- | 651.81 | -41.07 | -29.66 | -43.53 | -31.41 | -- | -- | -150,207.70 | -3,191.05 | -- | -- | 0.00 | -- | -99.37 | -- | -29.43 | -- | -- | -- |
| Enliven Therapeutics Inc | 0.00 | 1.49m | 806.67m | 6.00 | 127.20 | 1.43 | 384.31 | -- | 0.1542 | 0.1542 | 0.00 | 13.71 | 0.00 | -- | -- | 0.00 | 1.60 | -45.58 | 1.69 | -49.29 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 102.90 | 46.43 | -- | -- |
| Twist Bioscience Corp | 227.84m | -212.61m | 823.49m | 989.00 | -- | 1.17 | -- | 3.61 | -3.76 | -3.76 | 4.03 | 12.33 | 0.243 | 3.16 | 6.38 | 230,376.10 | -22.67 | -35.74 | -24.74 | -39.83 | 41.33 | 32.59 | -93.32 | -136.18 | 6.23 | -- | 0.00 | -- | 53.83 | 80.02 | -43.24 | -- | 72.89 | -- |
Data as of May 30 2023. Currency figures normalised to PureTech Health PLC's reporting currency: US Dollar USD
0.29%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| AWM Investment Co., Inc.as of 31 Mar 2023 | 70.00k | 0.25% |
| Jane Street Capital LLCas of 31 Mar 2023 | 9.63k | 0.04% |
| UBS Financial Services, Inc.as of 31 Mar 2023 | 20.00 | 0.00% |
| UBS Securities LLCas of 31 Mar 2023 | 1.00 | 0.00% |
| Migdal Mutual Funds Ltd.as of 28 Feb 2022 | 0.00 | 0.00% |
| Old Mission Capital LLCas of 31 Mar 2023 | 0.00 | 0.00% |
More ▼
Data from 28 Feb 2023 - 31 Mar 2023Source: FactSet Research Systems Inc.
